Pulmonary Fibrosis Overview

Principles

Definition

Pulmonary fibrosis is a major academic concept and research domain focused on understanding the complex mechanisms of chronic, progressive fibrotic scarring of the lung parenchyma. This field investigates its diverse etiologies, pathological pathways, diagnostic methods, and the development of effective therapeutic strategies.

Ontological type

Pathophysiology

Therapeutic Strategies

Etiology and Risk Factors

Key developments

Key Figures

Pathology-Centered Framework era

In the pathology-centered framework era (1951–1995), Paul A. Katzenstein and colleagues defined the idiopathic pulmonary fibrosis spectrum by establishing the usual interstitial pneumonia pattern as the histologic cornerstone and linking it to clinical prognosis. Their clinicopathologic analyses, often with Jeffrey L. Myers, clarified features such as patchy fibrosis with temporal heterogeneity and prominent fibroblastic foci, enabling standardized histologic scoring. J. Behr and collaborators contributed to standardized histologic criteria and emphasized extracellular matrix remodeling and collagen deposition as central mechanisms shaping fibrogenic biology. Together these contributions anchored clinico-radiologic-histologic correlation for diagnosis and prognosis and fostered cross-institutional comparability in this era.

TGF-β Signaling Axis era

Eric G. Neilson [1] was affiliated with the University of Pennsylvania [3] and Vanderbilt University [4] during this era. His key contribution, exemplified by the paper Epithelial-mesenchymal transition and its implications for fibrosis [7], was to illuminate epithelial-mesenchymal transition as a mechanism linking epithelial signaling to fibrogenesis, a finding that underscored the era's emphasis on TGF-β driven signaling cross-talk. Raghu Kalluri [2] was associated with the Harvard–MIT Division of Health Sciences and Technology [5] and Harvard University [6] during this period. In the same paper Epithelial-mesenchymal transition and its implications for fibrosis [7], his work advanced EMT-focused perspectives on fibroblast activation and signaling pathways, reinforcing the era's model in which TGF-β signaling and cross-talk orchestrate fibrogenesis.

Regenerative Failure Paradigm era

Dominique Valeyre [1] is associated with Université Paris Cité [3] and KU Leuven [4] during the Regenerative Failure Paradigm era. Her key contributions in this era include the Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [7], highlighting antifibrotic pharmacotherapy as a strategy to modulate regenerative failure and slow disease progression, which was pivotal for shifting the field toward biomarker-driven, combination approaches. Marilyn K. Glassberg [2] is affiliated with University of California, San Francisco [5] and University of Chicago [6] during this era. Her key contributions in this era include co-authoring the Pirfenidone CAPACITY trial [7], which helped anchor antifibrotic therapy in clinical practice and underscored the regenerative-failure paradigm by validating a pharmacologic approach to slow progression and inform multi-target strategies.